Skip to main content



Status: One Wales interim decision

Using the agreed starting and stopping criteria, rituximab can be made available within NHS Wales:

  • as a first-line add-on treatment for generalised myasthenia gravis in adults;
  • as a fourth-line or later treatment option for refractory generalised myasthenia gravis in adults.

Rituximab should be prescribed on the basis of lowest acquisition cost.

The risks and benefits of the off-label use of rituximab for these indications should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

At the latest review of this recommendation in July 2024, the decision by the One Wales Medicines Assessment group was to retain the current advice with no changes required.

Next review: this decision will be reviewed again after 12 months or earlier if new evidence becomes available.

 OWID with start stop criteria and review report. Rituximab for MG in adults (OW12 2024 review) (PDF, 150Kb)

Medicine details

Medicine name rituximab
Formulation Concentrate for solution for infusion
Reference number OW12

For the treatment of generalised  myasthenia gravis in adults.

Company Various
BNF chapter Musculoskeletal & joint diseases
Submission type One Wales
Status One Wales interim decision
Advice number OW12
AWMSG meeting date 19/04/2023
Date of issue 26/04/2023
Date of last review July 2024
Follow AWTTC: